Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

George Daniel Demetri, M.D.

Co-Author

This page shows the publications co-authored by George Demetri and Edwin Choy.
Connection Strength

1.661
  1. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma. Cancer. 2015 Apr 15; 121(8):1223-30.
    View in: PubMed
    Score: 0.633
  2. Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy. BMC Cancer. 2014 Nov 05; 14:813.
    View in: PubMed
    Score: 0.628
  3. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J Clin Oncol. 2012 Jul 01; 30(19):2401-7.
    View in: PubMed
    Score: 0.132
  4. Tivantinib (ARQ 197), a selective inhibitor of MET, in patients with microphthalmia transcription factor-associated tumors: results of a multicenter phase 2 trial. Cancer. 2012 Dec 01; 118(23):5894-902.
    View in: PubMed
    Score: 0.132
  5. A phase II multi-strata study of lurbinectedin as a single agent or in combination with conventional chemotherapy in metastatic and/or unresectable sarcomas. Eur J Cancer. 2020 02; 126:21-32.
    View in: PubMed
    Score: 0.056
  6. Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial. Lancet. 2016 Apr 16; 387(10028):1629-37.
    View in: PubMed
    Score: 0.043
  7. Comparison of performance of various tumour response criteria in assessment of regorafenib activity in advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib. Eur J Cancer. 2014 Mar; 50(5):981-6.
    View in: PubMed
    Score: 0.037
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.